BACKGROUND: Resveratrol is a naturally occurring polyphenol believed to be cardioprotective. We previously demonstrated that resveratrol improves insulin signaling and glucose metabolism in liver and skeletal muscle of swine with metabolic syndrome. Although resveratrol has metabolic benefits in peripheral tissues, its effect on insulin signaling in ischemic myocardium (IM) is unclear. Therefore, we developed a clinically relevant swine model of metabolic syndrome and chronic myocardial ischemia to investigate the effects of resveratrol on insulin signaling in cardiac tissue. MATERIALS AND METHODS: Thirteen male Yorkshire swine were fed a high-cholesterol diet for 4 wk then underwent surgical placement of an ameroid constrictor to their circumflex artery to induce chronic myocardial ischemia. The high-cholesterol control group was given no drug (n = 7). The experimental group was provided the same diet and received supplemental resveratrol (100 mg/kg/d) (n = 6). Tissue was harvested 7 wk after ameroid placement for western blot and histological analyses. RESULTS: In IM, there was no significant difference between the two groups in the insulin signaling markers studied. In nonischemic myocardium, there was a significant decrease in phosphorylated AMP-activated protein kinase α (P = 0.021) in the group treated with resveratrol; otherwise, there were no significant differences between the groups. Immunostaining for glucose transporter 4 and Periodic acid-Schiff staining for myocardial glycogen stores was similar between the groups. CONCLUSIONS: Resveratrol has complex effects on glucose metabolism. Although prior studies demonstrated that resveratrol supplementation improves insulin sensitivity in peripheral tissues, in chronically IM, there are no significant alterations.
BACKGROUND:Resveratrol is a naturally occurring polyphenol believed to be cardioprotective. We previously demonstrated that resveratrol improves insulin signaling and glucose metabolism in liver and skeletal muscle of swine with metabolic syndrome. Although resveratrol has metabolic benefits in peripheral tissues, its effect on insulin signaling in ischemic myocardium (IM) is unclear. Therefore, we developed a clinically relevant swine model of metabolic syndrome and chronic myocardial ischemia to investigate the effects of resveratrol on insulin signaling in cardiac tissue. MATERIALS AND METHODS: Thirteen male Yorkshire swine were fed a high-cholesterol diet for 4 wk then underwent surgical placement of an ameroid constrictor to their circumflex artery to induce chronic myocardial ischemia. The high-cholesterol control group was given no drug (n = 7). The experimental group was provided the same diet and received supplemental resveratrol (100 mg/kg/d) (n = 6). Tissue was harvested 7 wk after ameroid placement for western blot and histological analyses. RESULTS: In IM, there was no significant difference between the two groups in the insulin signaling markers studied. In nonischemic myocardium, there was a significant decrease in phosphorylated AMP-activated protein kinase α (P = 0.021) in the group treated with resveratrol; otherwise, there were no significant differences between the groups. Immunostaining for glucose transporter 4 and Periodic acid-Schiff staining for myocardial glycogen stores was similar between the groups. CONCLUSIONS:Resveratrol has complex effects on glucose metabolism. Although prior studies demonstrated that resveratrol supplementation improves insulin sensitivity in peripheral tissues, in chronically IM, there are no significant alterations.
Authors: W Abbud; S Habinowski; J Z Zhang; J Kendrew; F S Elkairi; B E Kemp; L A Witters; F Ismail-Beigi Journal: Arch Biochem Biophys Date: 2000-08-15 Impact factor: 4.013
Authors: Y Fischer; J Thomas; L Sevilla; P Muñoz; C Becker; G Holman; I J Kozka; M Palacín; X Testar; H Kammermeier; A Zorzano Journal: J Biol Chem Date: 1997-03-14 Impact factor: 5.157
Authors: Raymond R Russell; Ji Li; David L Coven; Marc Pypaert; Christoph Zechner; Monica Palmeri; Frank J Giordano; James Mu; Morris J Birnbaum; Lawrence H Young Journal: J Clin Invest Date: 2004-08 Impact factor: 14.808
Authors: Michael P Robich; Louis M Chu; Thomas A Burgess; Jun Feng; Yuchi Han; Reza Nezafat; Michael P Leber; Roger J Laham; Warren J Manning; Frank W Sellke Journal: J Am Coll Surg Date: 2012-08-04 Impact factor: 6.113
Authors: Ashraf A Sabe; Nassrene Y Elmadhun; Ahmed A Sadek; Rahul S Dalal; Louis M Chu; Cesario Bianchi; Frank W Sellke Journal: J Card Surg Date: 2014-12-16 Impact factor: 1.620
Authors: Ashraf A Sabe; Ahmed A Sadek; Nassrene Y Elmadhun; Rahul S Dalal; Michael P Robich; Cesario Bianchi; Frank W Sellke Journal: J Med Food Date: 2015-01 Impact factor: 2.786
Authors: Ashraf A Sabe; Nassrene Y Elmadhun; Rahul S Dalal; Michael P Robich; Frank W Sellke Journal: J Thorac Cardiovasc Surg Date: 2013-11-20 Impact factor: 5.209